Selective inhibitors of cytosolic or secretory phospholipase A2 block TNF-induced activation of transcription factor nuclear factor-kappa B and expression of ICAM-1.
TNF signaling mechanisms involved in activation of transcription factor NF-kappaB were studied in the human keratinocyte cell line HaCaT. We show that TNF-induced activation of NF-kappaB was inhibited by the well-known selective inhibitors of cytosolic phospholipase A2 (cPLA2): the trifluoromethyl ketone analogue of arachidonic acid (AACOCF3) and methyl arachidonyl fluorophosphate. The trifluoromethyl ketone analogue of eicosapentaenoic acid (EPACOCF3) also suppressed TNF-induced NF-kappaB activation and inhibited in vitro cPLA2 enzyme activity with a similar potency as AACOCF3. The arachidonyl methyl ketone analogue (AACOCH3) and the eicosapentanoyl analogue (EPACHOHCF3), which both failed to inhibit cPLA2 enzyme activity in vitro, had no effect on TNF-induced NF-kappaB activation. TNF-induced NF-kappaB activation was also strongly reduced in cells stimulated in the presence of the secretory PLA2 (sPLA2) inhibitors 12-epi-scalaradial and LY311727. Addition of excess arachidonic acid suppressed the inhibitory effect of 12-epi-scalaradial and LY311727. Moreover, both methyl arachidonyl fluorophosphate and 12-epi-scalaradial blocked TNF-mediated enhancement of expression of ICAM-1. Activation of NF-kappaB by IL-1beta was markedly less sensitive to both cPLA2 and sPLA2 inhibitors. The results indicate that both cPLA2 and sPLA2 may be involved in the TNF signal transduction pathway leading to nuclear translocation of NF-kappaB and to NF-kappaB-activated gene expression in HaCaT cells.
UNIGEN-Center for Molecular Biology, Department of Physiology and Biomedical Engineering, Norwegian University of Science and Technology, Trondheim.
L
L
Thommesen
W
W
Sjursen
K
K
Gåsvik
W
W
Hanssen
O L
OL
Brekke
L
L
Skattebøl
A K
AK
Holmeide
T
T
Espevik
B
B
Johansen
A
A
Laegreid
D000818:Animals; D016718:Arachidonic Acid / Q000037:antagonists & inhibitors / Q000378:metabolism; D001095:Arachidonic Acids / Q000494:pharmacology; D002460:Cell Line; D003600:Cytosol / Q000187:drug effects / Q000201:enzymology* / Q000378:metabolism; D015118:Eicosapentaenoic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005822:Genetic Vectors; D006718:Homosteroids / Q000494:pharmacology; D006801:Humans; D007313:Insecta / Q000235:genetics; D018799:Intercellular Adhesion Molecule-1 / Q000096:biosynthesis* / Q000187:drug effects; D007375:Interleukin-1 / Q000037:antagonists & inhibitors / Q000494:pharmacology; D015603:Keratinocytes / Q000187:drug effects / Q000378:metabolism; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000378:metabolism; D063065:Organophosphonates / Q000494:pharmacology; D010741:Phospholipases A / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D054467:Phospholipases A2; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors; D054830:Sesterterpenes; D013729:Terpenes / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D015854:Up-Regulation / Q000187:drug effects
D001095:Arachidonic Acids; C114733:EPACOCF3; D004791:Enzyme Inhibitors; D006718:Homosteroids; D007375:Interleukin-1; D016328:NF-kappa B; D063065:Organophosphonates; D011994:Recombinant Proteins; D054830:Sesterterpenes; D013729:Terpenes; D014409:Tumor Necrosis Factor-alpha; C104810:methyl arachidonylfluorophosphonate; D018799:Intercellular Adhesion Molecule-1; D016718:Arachidonic Acid; C071197:scalaradial; D015118:Eicosapentaenoic Acid; D010741:Phospholipases A; D054467:Phospholipases A2